New Blood Tests Revolutionize Alzheimer's Diagnosis

What seemed impossible just five years ago is now saving patients from frightening brain scans and opening doors to earlier Alzheimer's treatment.

Dr. Howard Fillit, a geriatrician and Alzheimer's Drug Discovery Foundation co-founder, recently told a Palm Beach audience of over 200 people that he never believed blood tests for Alzheimer's would exist. Today, multiple companies are successfully bringing these tests to market, using ultra-sensitive equipment to measure key biomarkers in blood plasma.

The breakthrough came after decades of technological advancement. Before about 10 years ago, equipment simply wasn't sensitive enough to detect Alzheimer's markers in blood, Fillit explained at the Society of the Four Arts on January 28.

For years, brain scans were the primary diagnostic tool for Alzheimer's. While accurate, they can be frightening and expensive for patients facing potential diagnosis of the progressive disease, which causes memory decline, thought processing problems, and behavioral changes.

Now, a simple blood test can diagnose Alzheimer's with great precision. Current tests on the market look for two specific biomarkers, but newer versions measure even more, strengthening their accuracy.

C2N Diagnostics is seeking FDA approval for what Fillit calls the best test in a "bake-off" between six companies. Their Precivity test measures four biomarkers strongly correlated with Alzheimer's, representing the next evolution in blood testing technology.

Dr. Mark Monane, senior medical advisor for C2N Diagnostics, said the research behind the test was a multimillion-dollar endeavor. The Alzheimer's Drug Discovery Foundation provided major funding through a partnership spanning more than 20 years.

The foundation itself was born from personal tragedy. Ronald and Leonard Lauder created it in 1988 after their mother, cosmetics pioneer Estée Lauder, died from Alzheimer's disease.

Why This Inspires

These blood tests represent more than convenient diagnostics. They can measure how well treatments work during clinical trials and in everyday medical practice, potentially accelerating the discovery of new therapies.

The tests also remove a significant barrier to early diagnosis. When getting tested is as simple as a routine blood draw, more people may seek answers about worrying symptoms before the disease progresses.

Foundation chairs Tom and Heidi McWilliams sponsored the lecture series to share scientific breakthroughs directly with the public. "This disease can feel frightening for many," Heidi McWilliams said, adding that hearing from researchers provides "many reasons for hope."

The technology transforms what was once a difficult, anxiety-inducing diagnostic journey into something far more accessible for the millions of families touched by Alzheimer's.